Solid neoplasms are known to contain deficient vascular beds and areas of severe vascular insufficiency, and as a result, may develop regions containing hypoxic tumor cells. These malignant cells, which frequently constitute 5 to 30% of the total viable tumor cell population, may form a therapeutically resistant group within solid tumors. Thus, hypoxic neoplastic cells may capable of proliferating and causing tumor regrowth after treatment that produces tumor regression. The overall objectives of this proposal are aimed at exploiting the fact that hypoxic cells in solid tumors exits in an environment conducive to reductive processes by utilizing chemotherapeutic agents that become cytotoxic after reductive activation. Therapeutic drug regiments will be developed that will have use in the treatment of cancer in man based upon pharmacological and biochemical considerations. Specifically, we will (a) study a variety of bioeductive alkylating agents including mitomycin antibiotics, aziridinyl quinone sulfonate and 1-haloalkyl-2-nitroimidazoles; (b) synthesize more efficacious agents of the quinone and nitroimidazole classes and hydroxylamino derivatives of purine and pyrimidine antimetabolites; (c) ascertain the cytotoxic properties of these agents toward neoplastic cell in vitro under both aerobic and hypoxic conditions; (d) determine the potential antineoplastic activity of these materials in animals bearing transplanted murine tumors; (e) study the mechanism of action of these agents in normal and neoplastic cells; and (f) evaluate the effectiveness of combinations of drugs and other modialities employed to eradicate oxygenated and hypoxic cellular compartments of solid tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA043659-05
Application #
3185949
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1987-01-01
Project End
1991-12-31
Budget Start
1991-01-01
Budget End
1991-12-31
Support Year
5
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Yale University
Department
Type
Schools of Medicine
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Lin, T S; Zhu, L Y; Xu, S P et al. (1991) Synthesis and antimalarial activity of 2-aziridinyl- and 2,3-bis(aziridinyl)-1,4-naphthoquinonyl sulfonate and acylate derivatives. J Med Chem 34:1634-9
Saari, W S; Schwering, J E; Lyle, P A et al. (1991) Synthesis and evaluation of some nitrobenzenesulfonamides containing nitroisopropyl and (ureidooxy)methyl groups as novel hypoxic cell selective cytotoxic agents. J Med Chem 34:3132-8
Keyes, S R; Loomis, R; DiGiovanna, M P et al. (1991) Cytotoxicity and DNA crosslinks produced by mitomycin analogs in aerobic and hypoxic EMT6 cells. Cancer Commun 3:351-6
Tomasz, M; Hughes, C S; Chowdary, D et al. (1991) Isolation, identification, and assay of [3H]-porfiromycin adducts of EMT6 mouse mammary tumor cell DNA: effects of hypoxia and dicumarol on adduct patterns. Cancer Commun 3:213-23
Keyes, S R; Rockwell, S; Kennedy, K A et al. (1991) Distribution of porfiromycin in EMT6 solid tumors and normal tissues of BALB/c mice. J Natl Cancer Inst 83:632-7
Rockwell, S; Keyes, S R; Loomis, R et al. (1991) Activity of C-7 substituted cyclic acetal derivatives of mitomycin C and porfiromycin against hypoxic and oxygenated EMT6 carcinoma cells in vitro and in vivo. Cancer Commun 3:191-8
Rockwell, S; Keyes, S R; Sartorelli, A C (1989) Modulation of the antineoplastic efficacy of mitomycin C by dicoumarol in vivo. Cancer Chemother Pharmacol 24:349-53
Rockwell, S; Keyes, S R; Sartorelli, A C (1989) Modulation of the cytotoxicity of porfiromycin by dicoumarol in vitro and in vivo. Anticancer Res 9:817-20
Lin, T S; Xu, S P; Zhu, L Y et al. (1989) Synthesis of 2,3-diaziridinyl-1,4-naphthoquinone sulfonate derivatives as potential antineoplastic agents. J Med Chem 32:1467-71
Pritsos, C A; Keyes, S R; Sartorelli, A C (1989) Effect of the superoxide dismutase inhibitor, diethyldithiocarbamate, on the cytotoxicity of mitomycin antibiotics. Cancer Biochem Biophys 10:289-98

Showing the most recent 10 out of 15 publications